Intra-Cellular Therapies Inc. (NASDAQ:ITCI) is reporting third quarter financial results on Monday 9th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, ITCI is expected to report 3Q20 loss of $ 1 per share from revenue of $ 5.86 million.
For the full year, analysts anticipate top line of $ 20.92 million, while looking forward to loss of $ 3.56 per share bottom line.
Previous Quarter Performance
Intra-Cellular Therapies Inc. unfold loss for the second quarter of $ 0.96 per share, from the revenue of $ 1.91 million. Street analysts expected Intra-Cellular Therapies Inc. to report loss of $ 0.91 per share on revenue of $ 3.03 million for the second quarter. The bottom line results missed street analysts by $ 0.05 or 5.49 percent, at the same time, top line results fell short of analysts by $ 1.12 million or 36.96 percent.
Stock Performance
On Friday, shares of Intra-Cellular Therapies Inc. has traded high as $ 25.07 and has cracked $ 24.17 on the downward trend, reaching $ 24.46 with volume of 598.20 thousand shares.
According to the previous trading day, closing price of $ 24.46, representing a 191.30 % increase from the 52 week low of $ 8.51 and a 43.09 % decrease over the 52 week high of $ 43.56.
The company has a market capital of $ 1.93 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Intra-Cellular Therapies Inc. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.intracellulartherapies.com
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinsons disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety.
